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Abstract
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A chemical library comprised of nineteen synthesized pyridyl disulfides that emulate the chemical
reactivity of allicin (garlic) was evaluated for antimicrobial activity against a panel of pathogenic
bacteria. Gram-positive species including vancomycin-intermediate and vancomycin-resistant
Staphylococcus aureus (VISA, VRSA) demonstrated the highest level of susceptibility toward
analogs with S-alkyl chains of 7–9 carbons in length. Further biological studies revealed that the
disulfides display synergy with vancomycin against VRSA, cause dispersal of S. aureus biofilms,
exhibit low cytotoxicity, and decelerate S. aureus metabolism. In final analysis, pyridyl disulfides
represent a novel class of mechanism-based antibacterial agents that have a potential application as
antibiotic adjuvants in combination therapy of S. aureus infections with reduced vancomycin
susceptibility.
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Staphylococcus aureus is a bacterial pathogen of great clinical significance to public health
[1]. Antibiotic-resistant forms including methicillin (MRSA), vancomycin-intermediate
(VISA), and vancomycin-resistant (VRSA) variants are associated with invasive diseases in
healthcare settings [2]. Multidrug-resistant (MDR) MRSA possessing resistance factors for
three or more antibiotic classes are further implicated in high rates of antimicrobial
treatment failures and chronic infections [1,2]. Consequentially, long-course treatment with
first-line vancomycin (VAN) has led to the emergence of VISA and VRSA as impending and
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formable threats to public health [3]. Alternative antibiotics and treatment strategies
therefore need to be developed to contend with these superbug infections.
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Allicin is a natural thiosulfinate in garlic (Allium sativum) that has been investigated for an
extensive range of medicinal applications including the treatment of bacterial infections [4].
Select Gram-positive pathogens including MRSA and Bacillus anthracis (anthrax) exhibit
susceptibility to allicin at clinically-relevant minimum inhibitory concentrations (MICs) [5].
In addition, synergism with VAN has been reported for VAN-resistant Enterococcus (VRE)
[6]. By chemical nature, allicin is electrophilic (δ+) and reacts with thiophilic, sulfhydrylbaring molecules such as cysteine, glutathione (GSH) and coenzyme A (CoASH) [7].
Multiple mechanisms have been proposed for the antibacterial action of allicin [4]. Each
mutually involves a thiol-disulfide exchange reaction between the S-allyl constituent of
allicin and the terminal thiol of an intracellular metabolite, coenzymes, or enzyme [4].
Inhibition of fatty acid biosynthesis is thought to be a primary mechanism of growth
inhibition in bacteria [8]. Despite exhibiting antimicrobial properties against S. aureus, the
chemical and thermal instability of allicin [9] has led to efforts to identify analogs for
therapeutic development.

Author Manuscript

Pyridyl disulfides (1, PySSRs) are electrophilic reagents in the synthesis of asymmetric
(mixed) disulfides that mimic the chemical reactivity of allicin (Fig. 1) [10]. At
physiological pH, protonation of the pyridyl ring increases reactivity with thiophilic
substances to accelerate the thiol-disulfide exchange reaction. With a reaction profile
reminiscent of allicin, we embarked on an exploratory investigation to define the
antibacterial activity of the mechanism-based PySSRs as antibacterial agents. In this article,
the structure activity relationship (SAR) and pharmacodynamic properties of S(alkylthio)-2-pyridine disulfides are reported.

2. Results and discussion
2.1. Chemistry
2.1.1. Synthesis of S-(alkylthio)-2-pyridine disulfides—For the study, a focused
chemical library consisting of nineteen PySSR members 1a–s (Scheme 1) derived from
linear and branched thiols was prepared using classical organic chemistry. With exception of
S-(methylthio) analog 1a, the compounds were synthesized by a thiol-disulfide exchange
reaction from commercially available 2′2-dipyridyl disulfide and each respective thiol in
MeOH [10]. Unlike synthetic allicin [9,11], pyridyl disulfides 1b–s were stable at r.t.
following chromatographic purification. The only library member with which significant
decomposition occurred after isolation was the S-methyl analog 1a.

Author Manuscript

2.2. Biological studies
2.2.1. Antibacterial spectrum of activity—Preliminary antibacterial testing was
performed by the disc diffusion (Kirby-Bauer) assay [12] using VAN and cefotaxime as
comparators. The compounds were evaluated at equimolar concentrations of 10 μM in
DMSO against a ten species panel that included five S. aureus variants. The disulfides
exhibited narrow spectrum activity against Gram-positive bacteria including MDR S. aureus
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(Table S1). Only Gram-negative A. baumannii, E. coli, and E. cloacae were weakly or
partially inhibited by short chain analogs 1a–f. Significant growth inhibition was
indiscriminate for the majority of the PySSR analogs against B. anthracis and S.
epidermidis. Conversely, there was a striking correlation between the S-alkyl chain length
and zone diameter for S. aureus. Unbranched analogs with chain lengths of 5–9 carbons (1e–
i) exhibiting the highest degree of growth inhibition were carried forward for MIC
susceptibility testing. Synergism with VAN was also observed in the form of a bridging
effect between the neighboring zone of disulfide 1h (Fig. 2) and isobologram analysis was
performed by the checkerboard titration assay.
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2.2.2. Anti-MRSA activity—Susceptibility testing by the broth microdilution assay [12]
indicated that PySSR derivatives 1g–i of 7–9 carbon chains in length were the most effective
growth inhibitors of planktonic S. aureus (Table 1). The MIC range against a panel
comprised of six S. aureus variants was 1.56–25 μM (0.8–6.8 μg/mL) compared to 0.39 to
>50 μM (1.2–>150 μg/mL) for VAN. Reduced susceptibility was noted for linezolidresistant S. aureus (LRSA) and heterogeneous VISA (hVISA), but not for VISA and VanAtype VRSA [13] for disulfides 1g and 1h. Additional tests revealed that the disulfides disrupt
S. aureus biofilms and exhibited a bacteriostatic profile with MBC:MIC ratios >4, a metric
used to delineate bacteriostatic agents [14]. By contrast, VAN with a MBC:MIC ≤2 was
confirmed to be bactericidal. In the biofilm reduction (dispersal) assay [15], preformed S.
aureus biofilms were treated with 1–5× MIC of disulfide 1h for 20 h and their densities were
quantified by crystal violet (CV) staining. Fig. 3 shows that disulfide 1h disrupted
staphylococcal biofilms in a dose-dependent manner comparable to VAN.
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Susceptibility testing was expanded to include additional clinical isolates of VISA and
VRSA. The MIC90s for both variants was 12.5 μM for PySSRs 1g–i (Table 2). The
compounds notably retained their antibacterial effects against the majority of the VanA-type
VRSA strains. Accordingly, synergy testing was performed by isobologram analysis using
the classical checkerboard titration assay [16] in 96 well plate format to establish whether
the disulfides are able to lower the MIC of VAN in VRSA. In combination with 6.25 μM 1h,
susceptibility to VAN increased to MIC 1.56 μM from >50 μM (Fig. 4). The ΣFIC calculated
from the MICs for each of the five lowest 1h–VAN combinations equated to ≤0.5, a metric
used to define synergism [17].
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2.2.3. Resistance development studies—Development of antibiotic resistance in S.
aureus is a frequent cause of treatment failure [2,3]. To compare the rates of resistance
development in three variants of S. aureus (hVISA, VISA, and VRSA) to disulfide 1h, a
serial passage study was performed to monitor the changes in susceptibility in cultures
treated with 0.5× MIC of antibiotic for 20 h. Fig 5 shows that between passages 3 and 4,
hVISA followed by VRSA and VISA exhibited decreased susceptibility to the disulfide.
Between passages 5 and 7, the MIC of each test strain increased again by twofold or greater.
Most notable was the resistance development in hVISA from 12.5 μM to >50 μM indicating
that a subpopulation of resistant clones predominated after seven passages [18]. During the
course of the study, we also monitored alterations in the MICs when disulfide 1h was
combined with an equimolar amount of VAN. After seven passages, the only observed
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change was a twofold increase in the MIC with VRSA and hVISA between passages 2 and 4
(Fig. 5).
2.2.4. Effect of blood components studies—Due to their electrophilic and lipophilic
properties, it was anticipated that the antibacterial activity of PySSRs may be altered by one
or more components in bloods. Table 3 shows that media supplemented with GSH and 5–
10% fetal bovine serum (FBS) increased the MICs of disulfides 1g–i, which was attributed
to cleavage of the disulfide bond by GSH and serum protein binding, respectively. By
comparison, the MICs of OXA and VAN were not affected by the additives. We similarly
found that GSH and serum decreases the anti-MSSA activity of disulfiram (Antabuse™), a
FDA-approved disulfide drug for the treatment of chronic alcoholism [19]. Based on these
data, we concluded that in vivo dosing of PySSRs would have to compensate for blood
components in a manner similar to disulfiram and other disulfide drugs (e.g., prosultiamine).

Author Manuscript
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2.2.5. Cytotoxicity studies—Disulfides 1e–i were evaluated for cytotoxicity using
human breast MDA-MB-231 and liver HepG2 carcinoma cell lines. Fig. 6 shows that the
half-maximal inhibitory concentrations (IC50s) are greater than the MIC90s of 12.5 μM for
VISA and VRSA. For disulfide 1h, the IC50s were 74.9 and ≥ 100 μM for the respective cell
lines. The attenuated cytotoxic activity was attributed to the GSH-rich content in mammalian
cells. The thiophilic tripeptide has been shown to cancel out the antimicrobial activity of
allicin in bacteria through thiol-disulfide exchange [7] and it is believed that GSH inactivates
the PySSRs in mammalian cells. To this end, the Gram-positive species that exhibit
susceptibility to the disulfides 1e–i have low intracellular GSH levels and alternatively use
CoASH and bacillithiol in thiol-redox buffering [20]. A similar rationale is proposed for the
lack of antimicrobial activity in Gram-negative bacteria that contain high levels of cytosolic
GSH to maintain redox homeostasis [20,21].
2.2.6. Viability studies—To further examine the effects of PySSR 1h on bacteria
viability, we performed a series of growth and metabolic studies on S. aureus. Fig. 7A shows
that treatment with 1–2× MIC suppressed growth over a 20 h period while exposure to 0.25
and 0.5× MIC of 1h delayed proliferation for 10 and 15 h, respectively. Likewise, treatment
with 1 and 4× MIC attenuated the growth rate with little change in CFU numbers, which
again suggested that the PySSRs are bacteriostatic in nature (Fig. 7B). In a follow-up study
performed in HBSS with phenol red pH indicator, disulfide 1h was found to decelerate the
metabolism of glucose to organic acids in a manner comparable to triclosan at a
bacteriostatic test concentration (data not shown).

Author Manuscript

Bacteriostatic antibiotics have been previously shown to decelerate respiration and lower the
cellular metabolic state in S. aureus [22]. By contrast, bactericidal agents were found to
accelerate respiration and metabolism [23]. To further decipher the effect on metabolism, the
C12-resazurin viability assay was used to detect for alterations in the redox activity of S.
aureus treated with PySSR 1h. Fig. 8A shows that the disulfide decelerates metabolism in a
similar manner to the positive control NaF. Although these results were again consistent
with the bacteriostatic assessment, we further probed the effects on cell viability using the
LIVE/DEAD BacLight™ assay. In the experiment, membrane permeability (damage) as a
measure of cell viability is determined by comparing the green to red fluorescence ratio
Eur J Med Chem. Author manuscript; available in PMC 2019 January 01.
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(λem 535/595 nm) of bacteria co-labeled with SYTO™ 9 and propidium iodide. Fig. 8B
shows a negligible difference in membrane integrity between untreated and PySSR 1h
treatment groups. Conversely, a significant increase in membrane permeability was observed
for the pore-forming antibiotic nisin.
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2.2.7. Plasma membrane studies—With compelling data that revealed the disulfides to
be bacteriostatic agents that decelerate metabolism, we evaluated the effect of PySSRs on
electron transport through differential measurements of the membrane potential. In the
experiment, S. aureus was treated with either PySSR 1h, de-coupler CCCP (positive
control), or ciprofloxacin (negative control). The cells were then labeled with DiOC2(3) and
analyzed by flow cytometry at λex 488 nm. At 15 and 30 min intervals, the disulfide was
found to dissipate the membrane potential (ΔΨ) in both a time- and concentration-dependent
manner (Fig. 9). Rapid depolarization was observed within 15 min of treatment with 3–30
μM of the test drug. Between 15 and 30 min, moderate increases in membrane potentials
were observed for the groups treated with 1h (15–30 μM), but not the CCCP control.
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2.2.8. Cellular redox studies—The antagonistic effects on the membrane potential and
metabolism suggested that PySSRs could evoke a shift in the intracellular redox state.
Within this context, S. aureus employs CoASH with bacillithiol in place of GSH as the
major thiol involved in redox homeostasis [20,24]. Previous studies have shown that allicin
reduces cellular thiol levels and alters both the metabolic and redox states of cells [25,26].
Based on these previous findings, we postulated that PySSR 1h mimics the antibacterial
action of allicin by disrupting metabolism and thiol-redox buffering in S. aureus. To this end,
growth inhibition by the disulfides was partly attributed to alterations in cytosolic thiol levels
and the cellular redox state. To first establish whether PySSRs could decrease thiol levels
through–SR exchange (Fig. 1), PySSR 1h was incubated with equimolar CoASH and mass
spectroscopy was used to verify CoSSR formation (Fig. 10A).
With confirmation of a thiol-disulfide exchange with CoASH, it was believed that
perturbations in the cellular redox state is partly responsible for the antimicrobial effects of
PySSRs. We explored this premise by labeling treated S. aureus cells with the oxidantreactive probes nitroblue tetrazolium (NBT) [27] and 2′,7′-dicholorodihydrofluorescin-
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generating
diacetate (DCFH-DA) [28]. Triclosan was included in the experiments as a
positive control [29]. In the NBT assay, oxidation of the chromogenic probe was detected
within 1 h of treatment with disulfide 1h and triclosan in S. aureus (Fig. 10B). Increased
formation of oxidized DCFH [30] was also observed for PySSR 1h, but at a lower rate
compared to triclosan (Fig. 10C). It should be noted that although these experiments
revealed accelerated oxidation rates of the NBT and DCFH-DA probes, further studies are
needed to establish whether the inhibitory effects of disulfide-based antibacterial drugs can
be attributed to a shift in the cellular redox state in S. aureus [31].

3. Conclusions
S. aureus is an invasive, toxigenic pathogen that can inflict disease on every tissue, organ,
and system in the human body [1,2]. MDR strains with reduced glycopeptide susceptibility
are an emerging healthcare threat and new treatment strategies will be needed for patients
Eur J Med Chem. Author manuscript; available in PMC 2019 January 01.
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with these resistant infections [3]. Thio-sulfinates such as allicin represent a unique
mechanistic drug class whose activity spectrum is largely confined to Gram-positive species
that includes S. aureus [5]. In this report, we have identified pyridyl disulfides as stable
alternatives to allicin with a similar narrow spectrum profile. All twenty-five strains of S.
aureus used in the study exhibited the highest susceptibility to PySSR derivatives bound
with linear S-alkyl chains of 7–9 carbons in length. Quality control MRSA 43300 and VanAtype VRSA were equally susceptible to the disulfides; however, LRSA and hVISA were less
sensitive for undetermined reasons. The latter was also found to have a higher rate of
resistance development compared to VISA and VRSA variants (Fig. 5). Our serial passage
experiment further revealed a lower rate of resistance selection when disulfide 1h was
combined with equimolar VAN versus the disulfide alone.
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In addition, the 8 carbon chain derivative 1h was identified in the disc diffusion assay as
having synergy with VAN through observation of a bridging effect between the adjacent
zones (Fig. 2) and further testing by isobologram analysis corroborated this relationship
(Fig. 4). Although a basis for the synergistic relationship in VRSA could not be definitively
established, we initiated preliminary investigative work to understand how PySSRs function
as a growth inhibitor of S. aureus. Their bacteriostatic nature suggests that the
pharmacodynamic effects are due to deceleration in cellular metabolism; however, PySSRs
may also evoke a shift in the redox state that triggers perturbations of cell processes involved
in growth [22]. Accordingly, an increase in the cellular oxidation state of bacteria has been
shown to alter metabolic activity (e.g., respiration) [22] and gene expression [32]. Redox
regulation in S. aureus is coordinated by low molecular weight thiols CoASH and
bacillithiol rather than GSH [20]. Increased intracellular oxidant levels results in a decrease
of the thiol:disulfide redox ratio and increased S-bacillithiolation of proteins, which is
believed to protect against cytotoxic effects in S. aureus [24,33].
Within this context, mass spectroscopy revealed that thiol-disulfide exchange occurs
between electrophilic PySSRs and thiophilic CoASH (Fig. 10A). Based on this finding, we
hypothesize that the antimicrobial action of PySSR is partially attributed to pro-oxidant
effects in S. aureus due to the thiol-disulfide exchange reactions in the cell. Increased
oxidation of NBT and DCFH-DA was observed with disulfide treatment (Fig. 10B and C);
however, further studies are needed to deduce the effects on the cellular redox state [31].
Another key finding of the investigation is that PySSR 1h decreases the membrane potential
(Fig. 9) without damaging the plasma membrane (Fig. 8B). Based on these data, it is
believed that the deceleration of metabolism by bacteriostatic PySSRs curbs respiration, deenergizing the cell membrane [22].

Author Manuscript

In final analysis, our data shows that PySSRs are bacteriostatic agents in Gram-positive
pathogens including MDR variants of S. aureus. The disulfides possess a narrow activity
spectrum and are thought to function as pro-oxidants in a manner reminiscent of allicin
[4,25]. Our studies found that the mechanism-based PySSRs suppress metabolism
presumably through interactions with thiophilic metabolites, coenzymes, and/or enzymes.
These data further suggest that PySSRs have more than one mechanism of action
responsible for the growth inhibition in S. aureus. Concomitantly, the onset of resistance
would expect to be lower for an antibacterial agent that inhibits multiple cell processes;
Eur J Med Chem. Author manuscript; available in PMC 2019 January 01.
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however, our serial passage experiments revealed the occurrence of resistance selection in S.
aureus treated with 0.5× MIC PySSR 1h. With these findings, it is believed that the
application of allicin-like drugs in antimicrobial therapy is limited to use as combination
treatments for Gram-positive bacterial infections with reduced VAN susceptibility. Future
investigations will focus on analyzing the potential place in therapy of disulfide-based drugs
as adjuvant antibiotics for MDR S. aureus infections.

4. Materials and methods
4.1. Chemistry
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Chemicals were purchased from commercial sources and used as received. Products were
purified by flash chromatography on 60–100 mesh silica and visualized by UV on TLC
plates (silica gel 60 F254). 1H and 13C NMRs were recorded on a 400 MHz NMR and
referenced to residual CDCl3. Abbreviations used in the description of resonances are as
follow: s (singlet); bs (broad singlet); d (doublet); t (triplet); q (quartet); qnt (quintet); m
(multiplet); dt (doublet of triplets); ddd (doublet of doublets of doublets).
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4.1.1. Synthesis of pyridyl disulfides 1; general procedure—Asymmetric S(alkylthio)-2-pyridine disulfides were prepared by a modified procedure of previously
reported methods [10]. To a stirring solution of 2′2-dipyridyl disulfide (0.75 mmol) and
AcOH (25 μL) in 9 mL of MeOH was added the corresponding thiol (0.75 mmol) in 1 mL of
MeOH at r.t. The mixture was stirred for 2–6 h and concentrated in vacuo. Flash silica gel
chromatography with 0–25% EtOAc in hexanes afforded the pure asymmetric disulfides 1b–
s as pale oils [10]. The S-methyl analog 1a was prepared from 2-mercaptopyridine (0.75
mmol) and S-methyl methanethiosulfonate (0.75 mmol) in 10 mL of MeOH. After stirring
for 2 h at r.t., the solvent was evaporated and the product was isolated as a pale oil by flash
silica gel chromatography with 3:1 hexanes:EtOAc. The spectroscopic data for disulfides
1e–i are provided.
4.1.1.1. S-(pentylthio)-2-pyridine (1e): 1H NMR (400 MHz, CDCl3) δ 8.45 (ddd, J = 4.9,
1.8, 0.9 Hz, 1H), 7.73 (dt, J = 8.1, 1.0 Hz, 1H), 7.69–7.59 (m, 1H), 7.07 (ddd, J = 7.4, 4.8,
1.1 Hz, 1H), 2.83–2.75 (m, 2H), 1.69 (q, J = 7.4 Hz, 2H), 1.43–1.24 (m, 5H), 0.88 (t, J = 7.2
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 160.7, 149.5, 136.9, 120.5, 119.5, 39.2, 30.7, 28.6,
22.3, 13.92; ESI–MS: m/z 214.1 [M+H]+
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4.1.1.2. S-(hexylthio)-2-pyridine (1f): 1H NMR (400 MHz, CDCl3) δ 8.45 (ddd, J = 4.9,
1.9, 0.9 Hz, 1H), 7.73 (dt, J = 8.1, 1.1 Hz, 1H), 7.63 (ddd, J = 8.1, 7.4, 1.8 Hz, 1H), 7.07
(ddd, J = 7.3, 4.8, 1.1 Hz, 1H), 2.83–2.75 (m, 2H), 1.75–1.61 (m, 1H), 1.44–1.28 (m, 4H),
1.32–1.21 (m, 6H), 0.87 (t, J = 7.5 Hz, 2H).; 13C NMR (101 MHz, CDCl3) δ 160.7, 149.5,
136.9, 120.4, 119.5, 39, 31.4, 28.9, 28.2, 22.5, 14; ESI–MS: m/z 228.2 [M+H]+.
4.1.1.3. S-(heptylthio)-2-pyridine (1g): 1H NMR (400 MHz, CDCl3) δ 8.45 (ddd, J = 4.8,
1.8, 0.9 Hz, 1H), 7.73 (dt, J = 8.1, 1.0 Hz, 1H), 7.63 (ddd, J = 8.1, 7.4, 1.8 Hz, 1H), 7.07
(ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 2.83–2.74 (m, 2H), 1.68 (q, J = 7.5 Hz, 2H), 1.43–1.28 (m,
3H), 1.25–1.40 (m, 8H), 0.91–0.82 (m, 3H).; 13C NMR (101 MHz, CDCl3) δ 160.7, 149.5,
136.9, 120.4, 119.5, 39, 31.7, 28.9, 28.4, 22.6, 14.1; ESI–MS: m/z 242.2 [M+H]+.
Eur J Med Chem. Author manuscript; available in PMC 2019 January 01.
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4.1.1.4. S-(octylthio)-2-pyridine (1h): 1H NMR (400 MHz, CDCl3) δ 8.44 (ddd, J = 4.8,
1.8, 0.9 Hz, 1H), 7.73 (dt, J = 8.1, 1.0 Hz, 1H), 7.63 (ddd, J = 8.1, 7.4, 1.9 Hz, 1H), 7.06
(ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 2.83–2.74 (m, 2H), 1.68 (qnt, J = 7.3 Hz, 2H), 1.43–1.17 (m,
10H), 0.92–0.81 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 160.7, 149.5, 136.9, 120.5,119.5,
39, 31.8, 29.2 (2), 29, 28.5, 22.7,14.1; ESI–MS: m/z 256.2 [M+H]+.
4.1.1.5. S-(nonylthio)-2-pyridine (1i): 1H NMR (400 MHz, CDCl3) δ 8.44 (ddd, J = 4.8,
1.8, 0.9 Hz, 1H), 7.73 (dt, J = 8.1, 1.0 Hz, 1H), 7.63 (ddd, J = 8.1, 7.4, 1.9 Hz, 1H), 7.06
(ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 2.85–2.67 (m, 2H), 1.68 (qnt, J = 7.3 Hz, 2H), 1.44–1.16 (m,
10H), 0.91–0.84 (m, 3H); 13C NMR (101 MHz, CDCl3) δ 160.7, 149.5, 136.9, 120.4, 119.5,
38, 31.8, 29.4, 29.2, 29.2, 28.9, 28.5, 22.6, 14.1; ESI–MS: m/z 270.2 [M+H]+
4.2. Biological studies
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Bacteria used in the study are listed in Tables S1 and S2 in the supplemental material.
Bacteria were initially grown on Mueller-Hinton agar (MHA) from freezer stocks stored at
−80 °C. Tryptic soy broth (TSB) and Luria-Bertani (LB) broth were used to grow starter
cultures from single colonies for testing. Mammalian cell lines used in the study were
propagated in Dulbecco’s Modified Eagle’s medium (DMEM) containing 10% fetal bovine
serum (FBS) from freezer stocks stored at −150 °C.
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4.2.1. MIC and MBC determination—Minimal inhibitory concentrations (MICs) were
determined by the broth microdilution method in 96-well flat bottom microplates [12]. A 0.5
McFarland standardized suspension prepared from an overnight culture was diluted to 1:100
in cation-adjusted Mueller Hinton broth (CAMHB) and treated with serial dilutions of test
agents for 20 h at 37 °C. The lowest drug concentration that gave inhibition of visual growth
was recorded as the MIC. The MIC50 and MIC90 values were defined as the lowest
concentration by which 50 and 90%, respectively, of the strains were inhibited by the test
agent. The minimal bactericidal concentrations (MBCs) were determined by spotting 5 μL
aliquots from each well on agar media. Following overnight incubation, the lowest
concentration to inhibit visual growth was recorded as the MBC.
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4.2.2. Biofilm reduction assay—To assess for biofilm dispersal, biofilms were grown in
a flat bottom 96-well microplate (Corning, Inc.) using 200 μL of a 1.5–2.0 × 105 inoculum
of S. aureus 25293 in CAMHB [15]. After 30 h incubation at 37 °C, the media was removed
by aspiration, the wells were washed with PBS, and the residual biofilms were treated with
1–5× MIC of test agent in 100 μL of CAMHB. Following 20 h incubation at 37 °C, the
media was removed and the biofilms were treated for 0.5 h with 200 μL of aqueous 0.1%
crystal violet. The staining solution was then discarded, the wells were washed with PBS,
and 200 μL of 30% acetic acid (vol/vol) was added to solubilize the dye retained by the
biofilms. Biofilm dispersal was assessed by comparing the optical absorption (OD595) of the
acetic acid solutions from the treated vs. untreated wells.
4.2.3. Synergy studies—Isobologram analysis of PySSR-VAN treatment combinations
was performed by the classical checkerboard titration assay [16]. Briefly, a 0.5 McFarland
suspension of VRSA HIP14300 was diluted to 1:100 in CAMHB and 50 μL was used to
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inoculate a 96-well plate containing twofold serial dilutions of PySSR and VAN in 50 μL
CAMHB. The plates were then sealed with adhesive film and incubated for 20 h at 37 °C.
Growth inhibition was visualized by MTT staining using DMSO to solubilize the formazan
product. The fractional inhibition (FIC) index was determined by the ratio of MIC of the
combination treatment to the MIC of PySSR 1h or VAN alone. The ΣFIC (FIC1h + FICVAN)
was interpreted according to the standard metrics: synergy ≤ 0.5; indifferent 0.5 < to ≤ 4;
antagonism > 4 [17].

Author Manuscript

4.2.4. Growth studies—An overnight inoculum of S. aureus 25293 was grown to an
OD600 of 0.1 and treated with 0, 0.25, 0.5, 1, and 2× MIC of test agents in a 96-well
microplate. The plate was incubated at 37 °C in a Multiskan GO microplate reader (Thermo
Fisher Scientific, Inc.) and the OD600 was measured at 1 h intervals following 30 s agitation.
The results were plotted using GraphPad Prism. Time-kill studies were performed using a
1:100 dilution of 0.5 McFarland suspension of S. aureus 25293 treated with 0,1, and 4× MIC
of test agent [34]. At time points 0, 1, 2, and 4 h, 10 μL samples were serially diluted in PBS
and streaked onto MHA plates to enumerate the bacteria. Colony forming units (CFUs) were
totaled after 30 h incubation and the data was plotted using GraphPad Prism.
4.2.5. Resistance studies—The serial passage assay [35] to determine resistance
development was performed using hVISA Mu3, VISA AR-217, and VRSA AIS 1000505
treated with 0.5× MIC of PySSR 1h ± equimolar VAN. A 0.5 McFarland standardized
suspension of each 0.5× MIC culture was diluted to 1:100 in CAMHB and treated with
serial dilutions of the test agents. Following incubation for 20 h at 37 °C, the MICs were
determined by visual inspection for each passage.

Author Manuscript

4.2.6. Cytotoxicity studies—The MTT assay was used to assess cellular viability by
measuring the NAD(P)H-dependent cellular oxidoreductase enzyme activity. The yellow dye
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is converted to an insoluble
blue formazan. Human breast adenocarcinoma cells MDA-MB-231 and human liver
carcinoma cells HepG2 were seeded at 5000 cells per well in a 96-well plate, and allowed to
adhere overnight. The next day, 0.001, 0.01, 0.1, 10, and 100 μM of test agents were added
to the cells and incubated for 72 h. At the end of the experiment, the media was removed and
MTT dye at 1 mg/mL in PBS pH 7.4 was added to each well and incubated for 2 h. The
MTT solution was then removed and pure DMSO added to each well and incubated in
orbital shaker for 30 min at 37 °C until the crystals were dissolved. The absorbance was
measured at OD570 in a BioTek Synergy H plate reader (BioTek Instruments, Inc.).

Author Manuscript

4.2.7. Viability studies—The LIVE/DEAD BacLight™ assay (Molecular Probes, Inc.) to
determine cell viability and membrane damage was performed on an overnight innocuum of
S. aureus 25293 grown to an OD600 of 0.4 in LB broth. The cells were harvested by
centrifugation (10,000 × g, 10 min, 4 °C), washed twice with PBS and resuspended in 100
mM phosphate buffer (KH2PO4/K2HPO4, pH 7.0) supplemented with 5 mM MgSO4. The
bacteria were then energized with glucose (20 mM final concentration) for 10 min at 37 °C
and treated with 1 or 5× MIC of test agent. Vehicle (DMSO; 5%) and 25 μg/mL nisin, a
pore-forming antibiotic, were used as controls [36]. After 5 min incubation, 100 μL samples
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were combined with 100 μL of a 2×BacLight™ staining reagent in a black flat bottom 96well microplate (Corning, Inc.) and mixed. The plate was covered and allow to stand at r.t. in
the absence of light. After 15 min, the fluorescence emission of green (λex 485 nm, λem 535
nm) to red (λex 485 nm, λem 595 nm) ratio was measured on a Filter Max F3 fluorescent
plate reader (Molecular Devices, Inc.). Membrane permeability (damage) as a measure of
cell viability was determined by comparing the green to red fluorescence ratio (λem 535/595
nm) between treatment groups.
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4.2.8. Metabolic activity assay—The Vybrant™Cell Metabolic assay (Invitrogen, Inc.)
to measure metabolic (redox) activity of viable bacterial cells was performed on an
overnight innocuum of S. aureus 25293 grown to an OD600 of 0.4 in LB broth. Cells were
treated with 0.25, 0.5, or 1× MIC of test agent. Vehicle (DMSO; 5%) and NaF (5 mM), an
inhibitor of glycolysis [36], were used as controls. After 15 min at 37 °C, aliquots of 200 μL
were combined with 5 μM C12-resazurin in a black flat bottom 96-well microplate and
incubated in the dark for 15 min. Metabolic activity was measured by the fluorescence
intensity of the reduced metabolite C12-resorufin (λex 550 nm, λem 595 nm).
4.2.9. Glucose metabolism—Phenol red pH indicator was used to detect for glucose
metabolism as a measure of increased acidity of the medium. A 90 μL innocuum of a OD600
1.0 suspension of S. aureus 25293 in Hank’s buffered salt solution (HBSS) was combined
with 150 μL of 70 μM phenol red in water and 10 μL of either 2 mM disulfide, triclosan,
vehicle (DMSO), or water in a 96-well plate. The plate was incubated at 37 °C in a
Multiskan GO microplate reader for 15 h with OD560 readings at 0.5 h intervals.

Author Manuscript

4.2.10. Membrane potential assay—The BacLight™ Bacterial Membrane Potential kit
(Molecular Probes, Inc.) was used to detect for drug-induced alterations in the proton
gradient of S. aureus. An overnight culture was diluted 1:100 in LB, incubated at 37 °C with
shaking for 2 h, and used to make a final 1:200 dilution for the experiment. Cells were
treated with PySSR 1h (3–30 μM), vehicle, (DMSO; 2%) or the respiratory decoupler
carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and incubated at 37 °C with shaking.
After 15 and 30 min, 200 μL samples were transferred to a fresh tube containing 2 μL of the
fluorescent membrane potential indicator dye DiOC2(3). DiOC2(3) emits green fluorescence
in all cells, but larger membrane potentials cause a shift towards red emission due to selfassociation of the dye at higher cytosolic concentrations [37]. After staining for 20 min,
bacteria were analyzed on a BD Biosciences FACSAria with the following parameters: λex
488 nm, green fluorescence filter 530/30 and red fluorescence filter 585/42. The resulting
data was processed using FlowJo v10.1 software (FlowJo, LLC).

Author Manuscript

4.2.11. NBT and DCFH-HA assays—The colorimetric nitroblue tetrazolium (NBT)
assay [27] to detect for alterations in intracellular oxidation rates was performed using a
OD600 1.5 suspension of S. aureus 25293 in HBSS. A 80 μL innocuum was combined with
150 μL aqueous solution of 1 mg/mL NBT and 10 μL of either 2 mM PySSR 1h, triclosan,
vehicle (DMSO), or water in a 96-well microplate and incubated with shaking for 1 h at
37 °C. The reaction was stopped with 10 μL 0.1 M HCl, the plate was centrifuged at 1500 ×
g for 10 min at 0 °C, and the supernatant was removed. The pellets were then treated with 25
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μL of DMSO, 10 μL 2 N KOH, and 50 μL of HBSS to solubilize the formazan product.
Intracellular oxidant species generation was measured by the intensity of blue coloration at
OD560.
The fluorometric 2′,7′–dichlorofluorescin diacetate (DCFH-HA) assay [28] was similarly
performed using a OD600 1.5 suspension of S. aureus 25293 in HBSS. To 80 μL of
inoculums in a black flat bottom 96-well microplate was added 5 μL of either 2 or 10 mM
PySSR 1h, 10 mM triclosan, vehicle (DMSO), or water followed by 15 μL of 100 μM
DCFH-HA in DMSO. Intracellular oxidation of deacylated DCFH was measured by the
intensity of fluorescence (λex 485 nm, λem 535 nm).
4.3. Statistical analyses

Author Manuscript

Data are presented as ± standard error of the mean (SEM). Statistical significance was
assessed by analysis of variance (ANOVA) with Tukey’s posttest for multiple comparisons
using Prism 5.0 (GraphPad Software, Inc) software. P values of < 0.05 were considered
significant.
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Fig. 1.

Mechanism of the thiol-disulfide exchange reaction for allicin-inspired pyridyl disulfides
(1).
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Fig. 2.

Disc diffusion (Kirby-Bauer) assay revealed synergistic activity of pyridyl disulfide 1h and
VAN against MRSA 43300.
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Fig. 3.

Effects of pyridyl disulfide 1h and VAN on S. aureus biofilm dispersal.
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Fig. 4.

The checkerboard assay revealed synergism between vancomycin and disulfide 1h against
VRSA HIP14300.
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Fig. 5.

Development of resistance by serial passage for disulfide 1h ± vancomycin.
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Fig. 6.
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Dose response curve of pyridyl disulfide 1e–i on breast (A) MDA-MB-231 and (B) liver
HepG2 carcinoma cell lines.
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Fig. 7.

Effects of pyridyl disulfide 1h on growth in MSSA 25923.
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Fig. 8.

Effects pyridyl disulfide 1h on MSSA 25923 viability. Shown are the (A) C12-resazurin and
(B) LIVE/DEAD BacLight™ assays for individual groups depicted as mean ± SEM (n = 3).
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Fig. 9.

Comparative effects on membrane potential. Shown are green fluorescence (left; 530/30
filter) and the ratio of red (585/42 filter) to green fluorescence for individual groups, shown
as mean ± SEM (right; n = 2).
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Fig. 10.

Effects of pyridyl disulfides on CoASH and cellular redox state. (A) Mass spectroscopy
revealed that S-(octylthio)-2-pyridine (1h) reacts with coenzyme A (CoASH) in situ by
thiol-disulfide exchange. (B) Effect of disulfide 1h in S. aureus by nitroblue tetrazolium
(NBT) staining. (C) Effect of disulfide 1h in S. aureus by dicholorodihydrofluorescindiacetate (DCFH-DA) staining.
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Scheme 1.

Chemical library of synthesized pyridyl disulfides (1) used in the study.
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MIC and MBC data for select disulfides against S. aureus.
Species | Strain

Test agenta

MICa

MBCa

ratiob

MSSA
ATCC 25923

1e

50

–

–

1f

25

–

–

1g

12.5

>50

>4:1

1h

12.5

>50

>4:1

1i

12.5

>50

>4:1

VAN

0.78

1.56

2:1

1e

50

–

–

1f

50

–

–

1g

6.25

>50

>8:1

1h

6.25

>50

>8:1

1i

6.25

>50

>8:1

VAN

0.39

0.78

2:1

1e

>50

–

–

1f

50

–

–

1g

25

–

–

1h

25

–

–

1i

25

–

–

VAN

0.78

1.56

2:1

1e

50

–

–

1f

50

–

–

1g

12.5

>50

>4:1

1h

12.5

>50

>4:1

1i

6.25

>50

>8:1

VAN

0.78

0.78

1:1

1e

50

–

–

1f

25

–

–

1g

3.13

25

8:1

1h

3.13

25

8:1

1i

1.56

25

16:1

VAN

3.13

3.13

1:1

1e

>50

–

–

1f

50

–

–

1g

6.25

>50

>8:1

1h

6.25

>50

>8:1

1i

12.5

>50

>4:1

VAN

>50

–

–

MRSA
ATCC 43300
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LRSA
SA LinR#14

hVISA Mu3
ATCC 700698
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VISA Mu50
ATCC 700699

VRSA
HIP11714
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MIC data for pyridyl disulfide 1e–i against S. aureus.
Variant (no. strains)

Test agent

MIC50a

MIC90a

Rangea

VISA (12)

1e

50

50

50–>50

1f

50

50

25–50

1g

12.5

12.5

3.13–25

1h

12.5

12.5

3.13–25

1i

6.25

12.5

1.56–25

VAN

3.13

3.13

1.56–3.13

1e

50

50

50–>50

1f

50

50

25–50

1g

6.25

12.5

3.13–12.5

1h

6.25

12.5

3.13–12.5

1i

6.25

12.5

3.13–12.5

VAN

>50

>50

12.5–>50

VRSA (10)
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12.5
25
25

serum, 5% vol/vol

serum, 10% vol/vol

50

glutathione, 100 μM

albumin, 0.05% vol/vol

12.5

1g

25

25

12.5

50

12.5

1h

MIC (μM)

null

Additive

50

25

25

50

12.5

1i

1.56

1.56

1.56

1.56

1.56

OXA

0.78

0.78

0.78

0.78

0.78

VAN
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Effect of blood components on susceptibility of MSSA 25923.
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